Hexaware Positioned as a Visionary in the 2026 Gartner® Magic Quadrant™ for Custom Software Development Services
Hexaware Positioned as a Visionary in the 2026 Gartner® Magic Quadrant™ for Custom Software Development Services
Gartner, Magic Quadrant for Custom Software Development Services, By Jaideep Thyagarajan, Ryan McKinney, Nathan Davie, 7 October 2026. Gartner and Magic Quadrant are trademarks of Gartner, Inc. and/or its affiliates. Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner’s business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose. This graphic was published by Gartner, Inc. as part of a larger research document and should be evaluated in the context of the entire document. The Gartner document is available upon request from Hexaware.
Blog
Share on
– Social campaigns cut clinical trial enrollment timelines by up to 70% versus traditional outreach.
– Biogen Idec’s MyHealthTeams partnership raised MS trial screening from 6 to 400 patients weekly.
– The #WhyWeDoResearch campaign reached 14 countries and engaged over 2,300 participants.
– Hexaware’s virtual trial platform delivered 2-times faster subject recruitment for a global CRO.
In 1943, the first modern clinical trial for common cold treatment was conducted in Great Britain. Over 1,000 patients from across the nation participated in this double-blinded trial, traveling an average of two to three hours by train or car to reach a single, centralized clinical trial location. The clinical investigators wrote the observations by hand, and it took 18 months to synthesize the results and generate a report. Looking back at this trial from a 21st-century perspective, it appears archaic: patients had to go to great lengths to participate, had little visibility into the trial results, and received minimal access to their own clinical trial data. Meanwhile, clinical investigators relied on a limited set of diagnostic tools and paper-based recording devices.
Fast forward to today, the landscape of clinical trials has undergone a dramatic transformation. Social media for life sciences has emerged as a powerful tool for pharmaceutical companies and Contract Research Organizations (CROs), reshaping clinical trials into faster, more inclusive, and patient-centered experiences.
This blog explores how integrating social platforms with decentralized clinical trial (DCT) strategies is revolutionizing the clinical research landscape, empowering organizations to stay ahead in the race for innovation.
The pandemic fast-tracked digital transformation within the life sciences sector, with clinical trials showcasing the most prominent advancements. One such advancement was the rise of decentralized clinical trials (DCTs), which highlighted the need for flexible and accessible trial designs, ultimately enhancing patient engagement and data collection efficiency.
Decentralized clinical trials are a modern approach to clinical research that allows for the execution of trial protocols outside of traditional centralized locations, such as hospitals or research centers.
According to the FDA, DCTs utilize telemedicine and local healthcare providers, enabling patients to participate from their homes through telehealth visits and familiar technologies like smartphones and wearables. This model eliminates the need for patients to travel repeatedly to a central site for enrollment, consent, data collection, or symptom monitoring. DCTs can be fully decentralized, where all aspects of the trial are conducted remotely, or hybrid, incorporating both virtual and in-person elements.
Social media platforms are driving real impact across the clinical trial lifecycle as follows:
While decentralized clinical trials allow patients to participate from home or nearby locations. When the reach of social media is combined with DCTs, it breaks down participation barriers and ensures diversity at scale. This integrated model has created new avenues for patient engagement, allowing participants to join trials from their homes and reducing the logistical barriers typically associated with traditional trial model
Leading pharma companies like Pfizer and Novartis are leveraging this blended approach to educate patients, recruit them, gather feedback, and build trust. Meanwhile, CROs are embracing these strategies by launching targeted campaigns aimed at specific patient populations. This approach enhances enrollment timelines and helps reduce recruitment costs significantly.
Benefits of this blended approach include:
The result? A more connected, inclusive, and transparent trial experience.
Here are three real-life examples of CROs and life sciences organizations effectively using social media to enhance clinical trials:
At Hexaware, we’ve built an AI-powered patient engagement platform that integrates clinical trial operations with social media insights, omnichannel communication, and real-time analytics.
Key capabilities include:
We partnered with the world’s largest CRO to develop an innovative, agile virtual trial platform, designed for scalability, speed, and patient-centricity. Our collaboration has led to remarkable outcomes:
Read the full case study here.
Social media and decentralized trials aren’t just tools—they’re strategic imperatives for modern clinical research. The organizations that embrace digital-first patient engagement are gaining real advantages in trial speed, diversity, and cost efficiency.
Ready to rethink your clinical trial strategy?
Let’s co-create the next generation of connected, inclusive, and outcomes-driven research. Contact us at marketing@hexaware.com to get started.
Social media for life sciences improves patient recruitment as follows:
DCTs differ from traditional trials in several ways as follows:
Integrating social media with decentralized clinical trials offers several advantages:
Social media campaigns support retention by:
Researchers maintain participant engagement as follows: